Valuation: CorMedix Inc.

Market Cap 385M 348M 321M 291M 549M 36.19B 565M 3.86B 1.53B 19.35B 1.44B 1.41B 61.58B P/E 2026 *
8.92x
P/E 2027 * 50.9x
Enterprise Value 385M 348M 321M 291M 549M 36.19B 565M 3.86B 1.53B 19.35B 1.44B 1.41B 61.58B EV / Sales 2026 *
1.14x
EV / Sales 2027 * 1.22x
Free-Float
92.54%
Yield 2026 *
-
Yield 2027 * -
1 day+1.96%
1 week-7.33%
Current month-13.43%
1 month-33.29%
3 months-39.43%
6 months-34.27%
Current year-57.61%
1 week 4.72
Extreme 4.72
5.68
1 month 4.72
Extreme 4.72
8.35
Current year 4.72
Extreme 4.72
12.29
1 year 4.72
Extreme 4.72
13.02
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 09/05/2022
Director of Finance/CFO 54 28/08/2025
Compliance Officer 66 11/12/2023
Director TitleAgeSince
Director/Board Member 67 05/08/2015
Chairman 81 02/08/2017
Director/Board Member 70 15/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Exercice

Director

97,818 0.1255%
29/08/26 Tax

Chief Financial Officer

-8,424 0.0108%
29/08/26 Tax

Compliance Officer

-8,424 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
+2.38%-7.33%-56.02%+58.52% 385M
+0.28%+5.38%+39.50%+132.88% 1,271B
+0.69%+3.34%+46.19%+93.35% 683B
+0.06%+0.94%+26.58%+112.09% 520B
-0.60%+3.36%+39.15%+68.96% 389B
-0.69%-0.54%+57.04%+42.42% 362B
-0.11%+0.63%+26.65%+58.26% 304B
+0.41%+0.23%+3.47%+36.24% 286B
-0.68%+0.91%+38.27%+74.21% 253B
+0.09%+0.53%+34.01%+123.91% 208B
Average +0.09%+0.81%+25.48%+80.08% 428B
Weighted average by Cap. -0.01%+2.67%+36.78%+94.89%

Financials

2026 *2027 *
Net sales 337M 304M 281M 254M 480M 31.65B 494M 3.37B 1.34B 16.92B 1.26B 1.24B 53.85B 316M 286M 264M 239M 451M 29.71B 464M 3.17B 1.26B 15.88B 1.19B 1.16B 50.56B
Net income 49.61M 44.86M 41.41M 37.48M 70.74M 4.66B 72.86M 497M 198M 2.49B 186M 182M 7.94B 8.31M 7.51M 6.93M 6.28M 11.84M 781M 12.2M 83.22M 33.07M 417M 31.17M 30.51M 1.33B
Net Debt - -
Projected Income Statement - Annual - CorMedix Inc.
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
13/11/26 US$4.925 +1.76% 478,946
12/11/26 US$4.840 -8.68% 3,681,872
11/11/26 US$5.300 -1.30% 1,626,094
10/11/26 US$5.370 -1.83% 2,341,748
09/11/26 US$5.470 +2.82% 2,330,247
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - CorMedix Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.840USD
Average target price
15.60USD
Spread / Average Target
+222.31%
  1. Stock Market
  2. Stocks
  3. CRMD Stock